Volume 25, Number 7—July 2019
Synopsis
Added Value of Comprehensive Program to Provide Universal Access to Care for Sputum Smear–Negative Drug-Resistant Tuberculosis, China
Fei Huang, Susan van den Hof, Yan Qu, You Li, Hui Zhang
, Lixia Wang, Miaomiao Sun, Wei Lu, Shuangyi Hou, Tianhua Zhang, Shitong Huan, Daniel P. Chin, and Frank Cobelens
, Lixia Wang, Miaomiao Sun, Wei Lu, Shuangyi Hou, Tianhua Zhang, Shitong Huan, Daniel P. Chin, and Frank Cobelens
Table 2
Drug resistance testing and results by prefecture and smear status in study of comprehensive program to provide universal access to care for sputum smear–negative drug-resistant tuberculosis, China*
| Characteristic | Yichang, no. (%) |
Zhenjiang, no. (%) |
|||
|---|---|---|---|---|---|
| Baseline | Intervention | Baseline | Intervention | ||
| Smear-positive patients | |||||
| Patients given a diagnosis | 1,177 (100) | 949 (100) | 631 (100) | 560 (100) | |
| Patients tested for drug resistance | 36 (3.1) | 863 (90.9) | 470 (74.5) | 518 (92.5) | |
| Rapid resistance result available | 36 (3.1) | 828 (87.2) | 453 (71.8) | 457 (81.6) | |
| Drug resistance test result | |||||
| No resistance to rifampin and isoniazid | 24 (2.0) | 715 (75.3) | 405 (64.2) | 389 (69.5) | |
| Resistance to only isoniazid | 3 (0.3) | 46 (4.8) | 26 (4.1) | 38 (6.8) | |
| Any rifampin resistance | 9 (0.8) | 67 (7.1) | 21 (3.3) | 30 (5.4) | |
| MDR TB | 6 (0.5) | 30 (3.2) | 14 (2.2) | 18 (3.2) | |
| Resistance to only rifampin |
3 (0.3) |
37 (3.9) |
7 (1.1) |
12 (2.1) |
|
| Smear-negative patients | |||||
| Patients given a diagnosis | 2,258 (100) | 2,055 (100) | 1,156 (100) | 800 (100) | |
| Cultures performed | 14 (0.6) | 1,842 (89.6) | 19 (1.6) | 749 (93.6) | |
| Cultures positive | 12 (0.5) | 358 (17.4) | 19 (1.6) | 52 (6.5) | |
| Patients tested for drug resistance† | 1 (<0.1) | 352 (17.1) | 22 (1.9) | 53 (6.6) | |
| Rapid resistance result available | 1 (<0.1) | 330 (16.1) | 21 (1.8) | 47 (5.9) | |
| Drug resistance test result | |||||
| No resistance to rifampin and isoniazid | 0 | 299 (14.5) | 19 (1.6) | 43 (5.4) | |
| Resistance to only isoniazid | 1 (<0.1) | 19 (0.9) | 0 | 3 (0.4) | |
| Any rifampin resistance‡ | 0 | 12 (0.6) | 2 (0.2) | 1 (0.1) | |
| MDR TB | 0 | 10 (0.5) | 2 (0.2) | 1 (0.1) | |
| Resistance to only rifampin | 0 | 2 (0.1) | 0 | 0 | |
*Differences in numbers of patients tested and numbers with a test result reflect indeterminate test results. MDR TB, multidrug-resistant tuberculosis (i.e., resistant to rifampin and isoniazid); TB, tuberculosis.
†Including 10 smear-negative patients who had no culture results and 24 smear-negative culture-negative patients for whom a line-probe assay was performed directly for sputum.
‡Including 2 smear-negative patients for whom a line-probe assay was performed directly for sputum.
Page created: June 17, 2019
Page updated: June 17, 2019
Page reviewed: June 17, 2019
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.